| Q46345591 | Animal models of tuberculosis |
| Q35605940 | Approaches towards the development of a vaccine against tuberculosis: recombinant BCG and DNA vaccine |
| Q83858682 | BCG vaccination of guinea pigs modulates Mycobacterium tuberculosis-induced CCL5 (RANTES) production in vitro and in vivo |
| Q46287030 | BCG vaccine elicits both T-cell mediated and humoral immune responses directed against mycobacterial lipid components |
| Q33756046 | Beyond BCG: the potential for a more effective TB vaccine |
| Q40968692 | Characterization of the culture filtrate-specific cytotoxic T lymphocyte response induced by Bacillus Calmette-Guérin vaccination in H-2b mice |
| Q30159872 | Computational identification of beta-barrel outer-membrane proteins in Mycobacterium tuberculosis predicted proteomes as putative vaccine candidates. |
| Q34004438 | CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis |
| Q57598814 | Cultivation of Mycobacterium bovis BCG in bioreactors |
| Q36744717 | Current status of TB vaccines |
| Q57598880 | Cytolytic T-cell responses to human dendritic cells and macrophages infected with Mycobacterium bovis BCG and recombinant BCG secreting listeriolysin |
| Q57038792 | Defining putative T cell epitopes from PE and PPE families of proteins of Mycobacterium tuberculosis with vaccine potential |
| Q33631222 | Dendritic cells in chronic mycobacterial granulomas restrict local anti-bacterial T cell response in a murine model. |
| Q34053027 | Dose of incorporated immunodominant antigen in recombinant BCG impacts modestly on Th1 immune response and protective efficiency against Mycobacterium tuberculosis in mice. |
| Q84293395 | Dry-powder pulmonary insufflation in the mouse for application to vaccine or drug studies |
| Q35669625 | Drying a tuberculosis vaccine without freezing |
| Q28487559 | Elements of signal transduction in Mycobacterium tuberculosis: in vitro phosphorylation and in vivo expression of the response regulator MtrA |
| Q33755534 | Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis |
| Q44070977 | Expression of interferon-gamma and tumour necrosis factor-alpha messenger RNA does not correlate with protection in guinea pigs challenged with virulent Mycobacterium tuberculosis by the respiratory route |
| Q34000497 | Generation of CD8(+) T-cell responses to Mycobacterium bovis and mycobacterial antigen in experimental bovine tuberculosis |
| Q61623133 | Identification of distinct lymphocyte subsets responding to subcellular fractions of Mycobacterium bovis bacille calmette-Guérin (BCG) |
| Q41720895 | Immunological relatedness of the protective mechanisms against tuberculosis and cancer |
| Q37693346 | Immunotherapy against metastatic bladder cancer by combined administration of granulocyte macrophage-colony stimulating factor and interleukin-2 surface modified MB49 bladder cancer stem cells vaccine |
| Q40524651 | Improved immunogenicity of a tuberculosis DNA vaccine encoding ESAT6 by DNA priming and protein boosting |
| Q35567441 | Induction of cytotoxic T-cell responses against culture filtrate antigens in Mycobacterium bovis bacillus Calmette-Guérin-infected mice |
| Q34009687 | Influence of Mycobacterium bovis bacillus Calmette Guérin on in vitro induction of CD1 molecules in human adherent mononuclear cells |
| Q36044987 | Interleukin-15 as an Immune Adjuvant To Increase the Efficacy of Mycobacterium bovis Bacillus Calmette-Guérin Vaccination |
| Q34280918 | Intracellular bacteria as targets and carriers for vaccination |
| Q38031924 | Is interferon-gamma the right marker for bacille Calmette-Guérin-induced immune protection? The missing link in our understanding of tuberculosis immunology |
| Q36793138 | Kinetics of IFN-gamma and TNF-alpha gene expression and their relationship with disease progression after infection with Mycobacterium tuberculosis in guinea pigs |
| Q44559005 | Lung macrophages from bacille Calmette-Guérin-vaccinated guinea pigs suppress T cell proliferation but restrict intracellular growth of M. tuberculosis after recombinant guinea pig interferon-gamma activation |
| Q34722855 | Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice |
| Q36069312 | Mycobacterium bovis Bacille Calmette-Guérin strains secreting listeriolysin of Listeria monocytogenes |
| Q47159990 | Mycobacterium tuberculosis components expressed during chronic infection of the lung contribute to long-term control of pulmonary tuberculosis in mice. |
| Q39829844 | Production of tumor necrosis factor and nitric oxide by macrophages infected with live and dead mycobacteria and their suppression by an interleukin-10-secreting recombinant. |
| Q53557432 | Protection of mice against Mycobacterium tuberculosis infection by immunization with aqueous fraction of Triton X-100-soluble cell wall proteins. |
| Q54240070 | Protective efficacy of recombinant BCG over-expressing protective, stage-specific antigens of Mycobacterium tuberculosis. |
| Q30332918 | Recent progress in the development and testing of vaccines against human tuberculosis. |
| Q30387447 | Recombinant Mycobacterium bovis BCG as an HIV vaccine vector |
| Q37251175 | The guinea pig as a model of infectious diseases. |
| Q42663381 | The phosphatidyl-myo-inositol anchor of the lipoarabinomannans from Mycobacterium bovis bacillus Calmette Guérin. Heterogeneity, structure, and role in the regulation of cytokine secretion |
| Q44273488 | Ultraviolet radiation reduces resistance to Mycobacterium tuberculosis infection in BCG-vaccinated guinea pigs |